AlzeCure Pharma places 9,926,099 shares with QuantumCell at SEK 4.91 each

• AlzeCure Pharma set a directed share issue to QuantumCell as part of the ACD856 out-licensing and collaboration agreement.
• QuantumCell will subscribe for 9,926,099 new shares at SEK 4.91 each, paid in cash.
• The placement implies about 6.7% dilution; total shares to rise to 147,823,445 once registered.
• The transaction corresponds to a USD 5 million equity component previously disclosed under the agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzeCure Pharma AB published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.